Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25B | P30305 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29965655 | 1.00 | CDC25B (0.39) | CDC25B | |
| Methyl Alcohol SCHEMBL18284553 | 0.94 | CDC25B (0.36) | CDC25B | |
| SCHEMBL4574418 | 0.90 | CDC25B (0.38) | CDC25B | |
| SCHEMBL7737681 | 0.87 | CDC25B (0.41) | CDC25B | |
| Pyrazole SCHEMBL7031994 | 0.82 | — | — | |
| SCHEMBL2975734 | 0.77 | CDC25B (0.48) | CDC25B | |
| SCHEMBL30276371 | 0.73 | CDC25B (0.31) | CDC25B | |
| SCHEMBL4588164 | 0.73 | CDC25B (0.31) | CDC25B | |
| SCHEMBL4020923 | 0.72 | CDC25B (0.36) | CDC25B | |
| SCHEMBL18155064 | 0.71 | CYP1A2 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036735-A | Pyrazolo [3,4-d ] pyrimidine-hydroxamic acid derivatives, synthetic method and application | 云南大学 | 2026-05-15 | — | — | CN | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | claimed |
| EP-4694980-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3 | Takeda Pharmaceutical Company Limited (JP) | 2026-02-18 | — | — | EP | claimed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | claimed |
| CN-119768172-A | Use of therapeutic agents having phosphodiesterase-7 inhibiting activity for the treatment and prevention of diseases associated with chronic fatigue, failure and/or intolerance to fatigue | 米托迪治愈有限责任公司 | 2025-04-04 | — | — | CN | claimed |
| CN-116354969-B | Pyrazolopyrimidinone elementary explosive and preparation method thereof | 四川轻化工大学 | 2025-03-21 | — | — | CN | claimed |
| CN-119390700-A | Pyrazolopyrimidinone derivative containing aniline unit, and preparation method and application thereof | 江苏海洋大学 | 2025-02-07 | — | — | CN | claimed |
| WO-2024214046-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AS INHIBITORS OF NLRP3 | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-17 | — | — | WO | claimed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | claimed |
| WO-2023221721-A1 | SHP2 INHIBITOR AND USE THEREOF | 安徽中科拓苒药物科学研究有限公司 | 2023-11-23 | — | — | WO | claimed |
| WO-2001010868-A1 | SYNTHESIS OF SUBSTITUTED PYRAZOLOPYRIMIDINES | NEUROCRINE BIOSCIENCES, INC. (US) | 2001-02-15 | — | — | WO | claimed |
| WO-2000012076-A9 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED INC (US) | 2000-08-17 | — | — | WO | claimed |
| EP-1027054-A1 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | Vivus, Inc. (US) | 2000-08-16 | — | — | EP | claimed |
| WO-2000037061-A2 | cGMP PDE 5 INHIBITORS FOR INHALATION IN THE TREATMENT OF SEXUAL DYSFUNCTION | NOVARTIS AG (CH) | 2000-06-29 | — | — | WO | claimed |
| WO-2000027848-A1 | PYRAZOLOPYRIMIDINONE DERIVATIVES FOR THE TREATMENT OF IMPOTENCE | DONG A PHARM. CO., LTD. (KR) | 2000-05-18 | — | — | WO | claimed |
| EP-0992240-A1 | THERAPEUTIC AGENT FOR ERECTION FAILURE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-04-12 | — | — | EP | claimed |
| US-6037346-A | Local administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction | VIVUS, INC. (US) | 2000-03-14 | — | — | US | claimed |
| WO-2000012076-A1 | NITROSATED AND NITROSYLATED PHOSPHODIESTERASE INHIBITORS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2000-03-09 | — | — | WO | claimed |
| WO-1999021558-A2 | LOCAL ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS FOR THE TREATMENT OF ERECTILE DYSFUNCTION | VIVUS, INC. (US) | 1999-05-06 | — | — | WO | claimed |
| WO-1999002161-A1 | USE OF PHOSPHORDIESTERASE INHIBITORS IN THE TREATMENT OF PROSTATIC DISEASES | FORSSMANN WOLF GEORG (DE) | 1999-01-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | CDC25B 1322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.